Presently, close to 50 companies are offering a variety of analytical testing solutions<Roots>

Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.

To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this ––mmr-and-tils-testing-2019–2030/253.html

The USD 860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:
 Type of test
 Laboratory Developed Tests (LDTs)
 Companion Diagnostic Tests (CDx)

 Type of disease indication
 Breast cancer
 Blood cancer
 Colon / Colorectal cancer
 Lung Cancer
 Melanoma
 Prostate Cancer

 Type of cancer biomarker
 TILs

 Type of analytical technique
 Next Generation Sequencing (NGS)
 Polymerase Chain Reaction (PCR)
 Immunohistochemistry (IHC)
 Others

 Key geographical regions
 North America
 Europe
 Japan
 China
 Australia

The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.”
report features the following companies, which we identified to be key players in this domain:
 Foundation Medicine
 NeoGenomics Laboratories
 Novogene
 Q2 Solutions
 Personal Genome Diagnostics
 Dr Lal PathLabs
 Shenzhen Yuce Biotechnology

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Product Competitiveness Analysis

6. Company Profiles

7. Publication Analysis

8. Innovative Designs for Biomarker-Based Clinical Trials

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Leave a Reply

Your email address will not be published. Required fields are marked *